The firm is a U.S.-based early-stage venture capital investor managing a micro-venture fund focused on emerging businesses across multiple industries, including life sciences and healthcare. The firm primarily invests at the Pre-Seed stage, with initial investments typically ranging from $100K–$250K. The firm maintains a selective healthcare allocation within its broader investment strategy and targets a limited number of new investments annually.
Within healthcare and life sciences, the firm focuses on healthcare analytics, digital health, medical devices, and select biotechnology opportunities. Areas of particular interest include data-driven healthcare technologies, gene therapies, and therapeutic approaches addressing autoimmune disorders. The firm evaluates opportunities based on differentiated technologies, early commercial potential, and the ability to address meaningful healthcare challenges. The firm is comfortable considering companies at the earliest stages of development.
From a company and management team perspective, the firm seeks emerging businesses developing innovative technologies with strong growth potential. The firm takes a flexible approach to governance and prefers board representation or observer rights when appropriate, although neither is a strict investment requirement.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
